NEW YORK – After two years of decline in 2022 and 2023, the 360Dx Top 30 rebounded in 2024, rising 4 percent year over year.

Editor’s Note: We will adjust the firms listed in the 360Dx Top 30 this month based on market caps at the end of 2024. Those changes will be reflected next month when we report on the stock ...

NEW YORK – Aspira Women's Health reported this week that it received written notice from the Nasdaq that the company had failed to regain compliance with the exchange's requirement to maintain a ...

The Nova Scotia-based firm's Multiplo Rapid TP/HIV Test is used to detect antibodies to HIV 1/2 and syphilis in a finger prick blood sample.

NEW YORK – In 2024, firms in the sepsis testing space made big moves to begin or expand the commercialization of tests that could help reduce the time-to-results, while many also secured funding to ...

Rapid Health allegedly submitted false claims to Medicare for over-the-counter COVID-19 tests that were not provided to Medicare beneficiaries.

Foresight said Roche failed to bring its trade-secret causes of action within the three-year statute of limitations.

NEW YORK — Laboratory-developed tests, FDA actions, the JP Morgan Healthcare Conference, and Roche — perhaps not surprisingly these subjects dominated the attention of 360Dx readers in 2024. Reader ...

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.